WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Wednesday that it has formed a collaboration with biomedical innovation company Sinorda Biomedicine for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.

Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics' experience and manufacturing capabilities in biologics development and manufacturing to advance SND006's preclinical pharmacology studies and clinical supply, accelerating the Investigational New Drug (IND) application process.

SND006 is an innovative bispecific antibody independently developed by Sinorda Biomedicine, for which the company holds worldwide rights.

Sinorda Biomedicine has completed in vitro functional validation studies of SND006 and plans to submit IND applications to China's National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) in 2026. In the future, the two companies intend to further expand their collaboration around Sinorda Biomedicine's potential pipeline, including multiple integrated projects spanning from molecule discovery to clinical manufacturing.